Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium After Simultaneous Pancreas-Kidney Transplantation

Transplantation Proceedings

Volumn 41, Issue 10, 2009, Pages 4265-4269

  Rangel, E B ^a   Melaragno, C S ^a   Sa J R ^a   Gonzalez, A M ^a   Linhares, M M ^a   Salzedas, A ^a   Medina Pestana, J O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIALYSIS; DIARRHEA; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTICOAGULANTS; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HEPARIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; PERITONEAL DIALYSIS; POSTOPERATIVE CARE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED;

EID: 71249089249     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.09.060     Document Type: Article

References (23)

1. Gruessner R.W., Sutherland D.E., Drangstveit M.B., et al. Mycophenolate mofetil in pancreas transplantation. Transplantation 66 (1998) 318
2. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for treatment of a first acute renal allograft rejection: a three-year follow-up. Transplantation 71 (2001) 1091
3. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2239
4. Behrend M. Adverse gastrintestinal effects of mycophenolate mofetil: aetiology, incidence, and management. Drug Saf 24 (2001) 645
5. Bunnapradist S., Lentine K.L., Burroughs T.E., et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102
6. Meier-Kriesche H.U., Ojo A.O., Leichtman A.B., et al. Effect of mycophenolate mofetil on long-term outcomes in African Americans renal transplant patients. J Am Soc Nephrol 11 (2000) 2366
7. Srinivas T.R., Kaplan B., Schold J.D., et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 80 2 suppl (2005) S211
8. Miller J., Mendez R., Pirsch J.D., et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 69 (2000) 875
9. Squifflet J.P., Bäckman L., Claesson K., et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 72 (2001) 63
10. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
11. Davies N.M., Grinyó J., Heading R., et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 22 (2007) 2440
12. Bunnapradist S., Neri L., Wong W., et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis 51 (2008) 478
13. Vinik A.I., Maser R.E., Mitchell B.D., et al. Diabetic autonomic neuropathy. Diabetes Care 26 (2003) 1553
14. Khurana A., McCuskey C.F., and Slavcheva E.G. Orthostatic hypotension in kidney pancreas transplant patients and its relation to preexisting autonomic neuropathy. Exp Clin Transplant 6 (2008) 127
15. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
16. Budde K., Curtis J., Knoll G., et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237
17. Arns W., Breuer S., Choudhury S., et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 19 (2005) 199
18. Tedesco-Silva H., Bastien M.C., Choi L., et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or myciphenolate mofetil. Transplant Proc 37 (2005) 852
19. Darji P., Vijayaraghavan R., Thiagarajan C.M., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 40 (2008) 2262
20. Chan L., Mulgaonkar S., Walker R., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290
21. Budde K., Glander P., Krämer B.K., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83 (2007) 417
22. Machnicki G., Ricci J.F., Brennan D.C., et al. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients. Pharmacoeconomics 26 (2008) 951
23. Lo A., Stratta R.J., Egidi M.F., et al. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis 3 (2001) 8